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Abstract
Background: Malignant fibrous histiocytomas (MFHs), or undifferentiated pleomorphic sarcomas, are in general high-grade
tumours with extensive chromosomal aberrations. In order to identify recurrent chromosomal regions of gain and loss, as
well as novel gene targets of potential importance for MFH development and/or progression, we have analysed DNA copy
number changes in 33 MFHs using microarray-based comparative genomic hybridisation (array CGH).
Principal findings: In general, the tumours showed numerous gains and losses of large chromosomal regions. The most
frequent minimal recurrent regions of gain were 1p33-p32.3, 1p31.3-p31.2 and 1p21.3 (all gained in 58% of the samples), as
well as 1q21.2-q21.3 and 20q13.2 (both 55%). The most frequent minimal recurrent regions of loss were 10q25.3-q26.11,
13q13.3-q14.2 and 13q14.3-q21.1 (all lost in 64% of the samples), as well as 2q36.3-q37.2 (61%), 1q41 (55%) and 16q12.1-
q12.2 (52%). Statistical analyses revealed that gain of 1p33-p32.3 and 1p21.3 was significantly associated with better patient
survival (P=0.021 and 0.046, respectively). Comparison with similar array CGH data from 44 leiomyosarcomas identified
seven chromosomal regions; 1p36.32-p35.2, 1p21.3-p21.1, 1q32.1-q42.13, 2q14.1-q22.2, 4q33-q34.3, 6p25.1-p21.32 and
7p22.3-p13, which were significantly different in copy number between the MFHs and leiomyosarcomas.
Conclusions: A number of recurrent regions of gain and loss have been identified, some of which were associated with
better patient survival. Several specific chromosomal regions with significant differences in copy number between MFHs
and leiomyosarcomas were identified, and these aberrations may be used as additional tools for the differential diagnosis of
MFHs and leiomyosarcomas.
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Introduction
The concept of malignant fibrous histiocytoma (MFH) has
changed during the last decades, and is now used to describe a
heterogeneous group of tumours without a specific known lineage
of differentiation and with fibroblastic/myofibroblastic features.
Tumours still classified as MFHs are also termed undifferentiated
high grade pleomorphic sarcomas (UPSs) according to the latest
World Health Organization (WHO) classification [1]. MFHs were
initially assigned to several subgroups; pleomorphic, myxoid, giant
cell and inflammatory, which are still used. However, several so-
called giant cell MFHs are now reclassified as other giant cell
sarcomas, and several so-called inflammatory MFHs are now
recognized to be dedifferentiated liposarcomas [2]. The so-called
myxoid MFHs are now termed myxofibrosarcomas [1], and this
second common subtype have a better prognosis than the most
common subtype, pleomorphic MFHs [3].
MFHs occur mainly late in life, between the age of 50 and 70
years, and the main locations are in the lower extremities followed
by the upper extremities and the retroperitoneum [3]. The main
exception is inflammatory MFHs, which are most often located in
the retroperitoneum. MFHs were previously regarded as the most
common soft tissue sarcoma of adults, and depending on the
criteria used for classification, MFHs still account for a
considerable portion of these tumours. Men are more frequently
affected than women, about 2/3 of the tumours occur in men [3].
MFHs are in general high-grade tumours, and the 5-year survival
is 65–70% [3].
Cytogenetic studies have revealed that most MFHs have
complex karyotypes with numerous aberrations, both numerical
and structural. Using chromosome-based comparative genomic
hybridization (CGH), recurrent gains of regions in 1p, 1q, 5p, 17p,
17q and 20q have frequently been observed, as well as losses of
regions in 2q, 9p, 10q, 11q and 13q [4,5,6,7,8,9,10,11]. High-level
amplification of the distal part of 13q has frequently been found
[5,6]. Gain of 17q has been associated with longer disease-free
survival and low risk of developing distant metastasis [9], whereas
gain of 7q32 has been associated with poor prognosis [5]. In
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15378addition, patients with gain of 1p31 showed a trend towards
decreased overall survival [5].
More recently, microarray-based CGH (array CGH) has been
used to analyse DNA copy number changes at higher resolution. In
order to identify specific genomic events and candidate targets that
may play a role in MFH development and/or progression, we have
used array CGH to map the distribution and frequency of DNA copy
number changes at high resolution in 33 MFH samples. Statistical
analyses were performed in order to identify possible correlations
between the experimental results and the clinical information. In
addition, the results were compared to array CGH data from 44
leiomyosarcomas in order to identify chromosomal aberrations
significantly different between the two tumour types, since their
differential diagnosis may be difficult due to histological similarities.
Materials and Methods
Tumour samples
Thirty-one human sarcomas classified as MFHs were selected
from a tumour collection at the Department of Tumour Biology at
Table 1. Clinical data of malignant fibrous histiocytomas.
Sample
Sample
origin
Patient
age/sex Diagnosis MFH Subtype Grade
1
Primary tumour
location
Size
(cm)
2
Metastasis
(months)
3 Status
Follow-up
(months)
4
MFH1 Rec 87/M MFH Myxofibrosarcoma 4 Lower arm 5 48 DD 50
MFH2x Rec 71/M MFH Spindle and pleomorphic 4 Upper trunk 19 4 DD 15
MFH4 Prim 77/M MFH Spindle and pleomorphic 4 Upper arm 15 MD DD 3
MFH7 Prim 68/M MFH Spindle and pleomorphic 4 Upper leg 6 NM DOC 74
MFH8 Met 76/M MFH Spindle and pleomorphic 4 Knee
5 61 5 D D 2 7
MFH9 Rec 57/F MFH Spindle and pleomorphic 4 Upper leg 3 NM DOC 346
MFH14 Prim 60/M MFH Spindle and pleomorphic 4 Knee 5.5 38 DD 82
MFH15 Prim 45/F MFH Pleomorphic with giant cells 4 Upper leg 20 6 DOC 6
MFH16 Rec 63/M MFH Myxofibrosarcoma 4 Upper trunk NA NM DOC 191
MFH18 Prim 61/M MFH Spindle and pleomorphic 4 Lower leg 18 16 DD 28
MFH19 Rec 71/F MFH Spindle and pleomorphic 4 Upper leg 5 NM NED 168
MFH20 Met 66/M MFH Spindle and pleomorphic 4 Upper leg
6 18 17 DD 40
MFH21 Prim 73/F MFH Spindle and pleomorphic 4 Upper trunk 15 7 DD 21
MFH24 Prim 92/F MFH Spindle and pleomorphic 4 Upper leg 13 NM NED 159
MFH25 Prim 47/F MFH Myxofibrosarcoma 4 Upper leg 20 NM NED 182
MFH27 Rec 60/M MFH Spindle and pleomorphic 3 Knee 7.5 34 DD 181
MFH30 Prim 56/M MFH Spindle and pleomorphic 4 Retroperitoneum 15 MD DD 3
MFH34 Rec 79/F MFH Spindle and pleomorphic 3 Upper trunk 1.7 NM DOC 80
MFH36 Prim 75/M MFH Myxofibrosarcoma 4 Shoulder 20 7 DD 14
MFH42 Prim 71/M MFH Pleomorphic with giant cells 4 Upper arm 7.5 4 DD 22
MFH44 Rec 80/F MFH Spindle and pleomorphic 4 Upper leg 13 NM DOC 15
MFH45 Prim 69/F MFH Spindle and pleomorphic 4 Upper arm 14 NM NED 119
MFH46 Prim 82/M MFH Spindle and pleomorphic 4 Upper leg 11 NM NED 86
MFH47 Prim 56/M MFH Spindle and pleomorphic 4 Upper leg 7 7 DD 19
MFH48 Prim 63/M MFH Spindle and pleomorphic 4 Lower leg 7 MD DD 100
MFH53 Prim 69/F MFH Pleomorphic with giant cells 4 Retroperitoneum 18 5 DD 10
MFH54 Prim 45/M MFH Myxofibrosarcoma 4 Upper leg 20 6 DD 7
MFH56 Prim 75/F MFH Spindle and pleomorphic 4 Upper arm 10 9 NED 85
MFH59 Prim 68/M MFH Spindle and pleomorphic 4 Upper trunk 10.5 MD DD 7
MFH60 Prim 58/F MFH Pleomorphic 4 Upper arm 11 9 DD 58
MFH61 Prim 66/M MFH Myxofibrosarcoma 4 Upper leg 9.5 NM NED 74
MFH73x Rec 82/F MFH Spindle cell 4 Lower arm 7 14 DOC 59
MFH76x Prim 69/F MFH Spindle and pleomorphic 4 Lower leg 10 8 DD 18
Abbreviations: x, xenograft; Rec, recurrence; Prim, primary tumour; Met: metastasis; M, male; F, female; MFH, malignant fibrous histiocytoma; NA, not available; MD,
metastasis at diagnosis; NM, no metastasis; DD, dead of disease; DOC, dead of other cause; NED, no evidence of disease;
1Grading is based on a four-tiered system used in the Scandinavian Sarcoma Group (SSG);
2Largest diameter of the tumour;
3Time to first metastasis from diagnosis;
4Time to last follow-up from diagnosis;
5Metastasis located in the lung;
6Metastasis located in the abdominal wall.
doi:10.1371/journal.pone.0015378.t001
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initially diagnosed as leiomyosarcomas were included in the study
after reclassification to MFH (MFH73x and MFH76x). All
tumours were revised at the time of the study by an expert
pathologist (B.B.) and diagnosed according to the current WHO
classification [1].
Clinical samples were collected immediately after surgery, cut
into small pieces, frozen in liquid nitrogen and stored at 270uC
until use. Some of the samples were grown subcutaneously in
immunodeficient mice as xenografts (suffix x). The clinical
information was retrieved from the MEDinsight database at The
Norwegian Radium Hospital. Clinical data for all samples are
given in Table 1.
Ethics Statement
The information given to the patients, the written consent used,
the collection of samples, and the research project were approved
by the ethical committee of Southern Norway (Project S-06133).
Human tumour samples were obtained with the corresponding
written consent given by the patients. Animal care was in
accordance with National and institutional guidelines and the
project approved by the National Committee on Research on
Animal Care (Project 1498).
Array CGH
he genomic microarray used contained 4,549 bacterial- and P1
artificial chromosome (BAC and PAC) clones representing the
human genome at approximately 1 Mb resolution, as well as the
minimal tiling-path between 1q12 and the beginning of 1q25.
Detailed information on the construction and preparation of the
microarray has been previously described [12]. The microarrays
were provided by the Norwegian Microarray Consortium (www.
microarray.no).
Array CGH was performed essentially as described previously
[12]. In brief, approximately 500 ng of DpnII-digested total
genomic DNA was labelled by random priming using BioPrime
DNA Labeling System (Invitrogen, California, USA) and Cy3-
dCTP (tumour) or Cy5-dCTP (reference) (PerkinElmer, Massa-
chusetts, USA). Labelled tumour and reference DNA were
combined together with 135 mg human Cot-1 DNA (Invitrogen).
Hybridisation was performed using an automated hybridisation
station, GeneTAC (Genomic Solutions/PerkinElmer), agitating
the hybridisation solution for 42–46 hours at 37uC. The arrays
were scanned using an Agilent G2565BA scanner (Agilent
Technologies, California, USA), and the images were segmented
using GenePix Pro 6.0 (Axon Laboratories, California, USA).
Further data processing, including filtering and normalization, was
performed using M-CGH as previously described [12,13].
Array CGH data analysis
The complete array CGH dataset for the 33 MFHs can be
viewed in the ArrayExpress microarray database (www.ebi.ac.uk/
arrayexpress, accession number E-MEXP-1804). Clones belonging
to chromosomes 1–22 with known unique chromosomal location
in Ensembl (www.ensembl.org, v33, Sep 2005) were considered for
analysis (3,351 clones). Due to experimental variation in normal
control experiments, 22 clones (0.7%) were discarded as described
previously [12]. In addition, clones with missing values in 10 or
more of the 33 samples were discarded, leaving 3,144 clones for
analysis. The remaining missing values were imputed via a K-
Nearest Neighbour algorithm normalization using ‘‘Significance
Analysis of Microarrays’’ (SAM) [14].
Clustering of all samples was performed using J-Express v. 2.7
[15], with average linkage (WPGMA) as the cluster method and
Pearson correlation as the distance metric. In order to determine
copy number changes, CGH-Explorer v. 3.1b was used [16].
‘‘Analysis of Copy Errors’’ (ACE) was performed using a false
discovery rate of 0.0001 and medium sensitivity. Chromosomal
segments showing gains or losses in at least 10 of 33 MFHs
(.30%) were used to identify minimal recurrent regions of
alteration.
Statistical analysis
Statistical analyses were performed using SPSS 15.0. Samples
were categorized based on the experimental results and compared
with the clinical data (Table 1). Overall survival was analyzed
using Kaplan-Meier survival curves and tested for significance
using the Log Rank test for all clinical variables and minimal
recurrent chromosomal regions altered. P values less than or equal
to 0.05 were considered to be statistically significant. Multivariate
analysis of experimental and clinical variables significantly
associated with survival was performed using Cox regression.
In order to identify chromosomal regions with significantly
different DNA copy number between two groups of samples, a
two-class unpaired t-test was performed using SAM [14]. Using
100 permutations and a false discovery rate of ,1%, a list of
genomic clones showing significant copy number differences was
generated. Chromosomal segments represented by multiple
significant clones (at least five significant clones with less than 10
non-significant clones between two significant clones) were
considered to be significantly different between the two groups.
Results
Recurrently altered chromosomal regions in malignant
fibrous histiocytomas
DNA copy number changes in a panel of 33 MFHs (Table 1)
were analysed using a 1 Mb resolution BAC and PAC genomic
microarray supplemented with the tiling-path between 1q12 and
the beginning of 1q25. Hierarchical clustering of all samples based
on the DNA copy number changes is shown in Figure 1. No
associations between the clustering pattern and the clinical features
were apparent. The panel consisted of mainly primary tumours
and recurrences, and SAM was used to identify chromosomal
regions with significantly different DNA copy number between the
two subtypes, but no differences were found.
Regions with significant DNA copy number changes were
identified in each sample using the ACE algorithm in CGH-
Explorer. The resulting frequency plot of gains and losses is shown
in Figure 2A, and a representative genome-wide ratio plot for this
type of tumours is shown in Figure 2B. The ratio plots for all
samples are shown in Figure S1. Minimal recurrent regions of
alteration identified by ACE in at least 10/33 (.30%) samples are
presented in Table 2. The complete list of data of all defined regions
of gain and loss from the ACE analysis is presented in Table S1.
In general, the samples showed numerous gains and losses of
large chromosomal regions. Of the 41 minimal recurrent regions
identified in the tumour samples, 24 represented gains and 17
Figure 1. Hierarchical clustering of MFHs. Hierarchical clustering of 33 MFHs using DNA copy number ratios relative to a pool of normal diploid
DNA. A total of 3,144 unique genomic clones are shown in chromosomal order from 1ptel to 22qtel. Chromosomes are indicated with black and grey
bars. Red, increases in DNA copy number; green, decreases in DNA copy number.
doi:10.1371/journal.pone.0015378.g001
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gain of regions in chromosome 1, 3–9, 12, 14, 17–20 and 22 was
identified (Table 2). The most frequent gains observed were in
chromosome 1, where minimal recurrent regions in 1p33-p32.3
(2.6 Mb), 1p31.3-p31.2 (5.5 Mb) and 1p21.3 (1.2 Mb) were gained
in 19/33 (58%) samples, whereas 1q21.2-q21.3 (0.5 Mb) was
gained in 18/33 (55%) samples. Gain of 20q13.2 (3.1 Mb) was
identified in 18/33 (55%) samples. Scattered high-level amplifica-
tion (log2 ratio.1) was observed in some of the tumours, but not
consistently in any region (see Table S1).
Figure 2. DNA copy number alterations. (A) Genome-wide frequency plot of copy number alterations identified by ACE in 33 MFHs. Red,
increases in DNA copy number; green, decreases in DNA copy number. (B) Whole genome DNA copy number profile of a representative MFH. Log2
ratio for each of the genomic clones is plotted according to chromosome position.
doi:10.1371/journal.pone.0015378.g002
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was identified in at least 30% of the tumours (Table 2). The most
frequent losses observed were in chromosome 10 and 13, where
minimal recurrent regions in 10q25.3-q26.11 (1.1 Mb), 13q13.3-
q14.2 (9.5 Mb) and 13q14.3-q21.1 (3.0 Mb) were lost in 21/33
(64%) samples. Loss of 2q36.3-q37.2 (6.9 Mb) was identified in
20/33 (61%) samples, whereas loss of 1q41 (2.3 Mb) was identified
in 18/33 (55%) samples and 16q12.1-q12.2 (3.5 Mb) in 17/33
(52%) samples. Scattered homozygous deletion (log2 ratio ,21)
was observed in some of the tumours, but not consistently in any
region (see Table S1).
Clinical correlatesStatistical analyses were performed in order to
identify possible correlations between the clinical information
(Table 1) and the minimal recurrent chromosomal regions altered
(Table 2). Survival analysis revealed that gain of 1p33-p32.3 and
1p21.3 was significantly associated with better patient survival
Table 2. Minimal recurrent regions altered in malignant fibrous histiocytomas (n=33).
Cytoband Aberration Start clone End clone Size (Mb) Frequency
1p33-p32.3 Gain RP1-86A18 RP4-631H13 2.6 19/33
1p31.3-p31.2 Gain RP11-5P4 RP5-1033K19 5.5 19/33
1p21.3 Gain RP11-17C2 RP11-413P11 1.2 19/33
1q21.2-q21.3 Gain RP11-363I22 RP11-316M1 0.5 18/33
1q41 Loss RP11-323K10 RP11-241C9 2.3 18/33
2p25.3-p25.1 Loss RP11-352J11 RP11-542B5 6.0 16/33
2q36.3-q37.2 Loss RP11-70L16 RP11-84G18 6.9 20/33
3p12.1-p11.2 Gain RP11-382L10 RP11-312H1 3.9 13/33
4q12 Gain RP11-738E22 RP11-355L4 0.2 15/33
5p14.3 Gain RP11-28P24 RP11-26L18 2.8 16/33
5q23.2-q31.3 Loss CTB-54G2 RP11-515C16 13.2 11/33
6q12-q13 Gain RP1-160B9 RP11-256L9 3.3 12/33
7p22.1 Gain RP11-172O13 RP1-42M2 0.4 14/33
7q11.21-q11.22 Gain RP11-340I6 RP11-471N21 8.5 14/33
7q36.1-q36.3 Loss RP11-24N19 CTB-3K23 10.4 10/33
8p23.2-p22 Loss RP11-245H16 RP11-44L18 9.9 16/33
8q22.1 Gain RP11-266D22 RP11-3D19 2.6 12/33
9p24.2-p24.1 Loss RP11-509J21 RP11-509D8 1.5 11/33
9q21.33-q31.3 Gain RP11-280P22 RP11-470J20 24.1 15/33
10q25.3-q26.11 Loss RP11-96N16 RP11-5G18 1.1 21/33
11q14.1 Loss RP11-118L16 RP11-482L11 1.9 16/33
11q14.3-q21 Loss RP11-268B20 RP11-83E23 2.2 16/33
11q23.3-q25 Loss CTD-3245B9 RP11-469N6 16.0 16/33
12p13.31-p13.1 Gain RP11-277E18 RP11-377D9 5.2 10/33
13q13.3-q14.2 Loss RP11-131F1 RP11-174I10 9.5 21/33
13q14.3-q21.1 Loss RP11-384G23 RP11-516G5 3.0 21/33
14q23.3-q31.3 Gain RP11-125H8 RP11-203D9 17.3 10/33
14q32.13-q32.33 Gain RP11-371E8 CTC-820M16 13.7 10/33
16p13.2 Loss RP11-114I12 RP11-148F10 1.3 10/33
16q12.1-q12.2 Loss RP11-305A7 RP11-467J12 3.5 17/33
17p12 Gain RP11-471L13 RP11-488L1 1.1 13/33
17p12-p11.2 Gain RP11-459E6 RP11-404D6 0.6 13/33
17p11.2 Gain RP11-189D22 RP11-78O7 1.8 13/33
17q21.31-q21.32 Gain RP5-843B9 RP11-510P20 0.9 12/33
18q11.2 Gain RP11-296E23 RP11-17J14 2.1 14/33
18q22.1-q23 Loss RP11-21L20 RP11-118I2 9.0 11/33
19q13.11-q13.2 Gain RP11-413M10 CTB-186G2 4.7 15/33
20q13.2 Gain RP5-994O24 RP11-6L15 3.1 18/33
22q12.2-q12.3 Gain RP1-76B20 CTA-415G2 3.4 10/33
22q12.3-q13.1 Gain LL22NC01-132D12 CTA-228A9 1.4 10/33
22q13.2-q13.33 Loss RP3-388M5 CTA-722E9 5.8 10/33
doi:10.1371/journal.pone.0015378.t002
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corresponding Kaplan-Meier plots with overall survival curves. In
contrast, male gender and metastasis at diagnosis were significantly
associated with poor patient survival (P=0.019 and 0.006,
respectively). The corresponding Kaplan-Meier plots are shown
in Figure S2.
Multivariate analysis was performed in order to identify the
most important prognostic factors. All experimental and clinical
variables that were significantly associated with poor survival were
tested using Cox regression. None of the variables were identified
as independent prognostic factors, but metastasis at diagnosis
showed almost significance as an independent prognostic factor
(relative risk 4.0, P=0.059).
Comparison with leiomyosarcomas
In order to investigate differences in DNA copy number
aberrations between MFHs and leiomyosarcomas, a comparison
with similar array CGH data from a panel of 44 leiomyosarcomas
([12] and Kresse et al., unpublished) was done. Figure 4A shows
the hierarchical clustering dendogram of the 33 MFHs and 44
leiomyosarcomas. Although smaller groups of MFHs and
leiomyosarcomas clustered separately, there were no overall
significant differences in the clustering pattern between the two
tumour types.
SAM was used to identify chromosomal regions with signifi-
cantly different DNA copy number between the MFHs and
leiomyosarcomas. Using a false discovery rate of ,1%, 156
genomic clones showing significant copy number differences
between the two tumour types were identified. Figure 4B shows
a graphical representation of the genomic clones, and the
complete list is given in Table S2. Seven chromosomal segments
represented by multiple significant clones were identified; 1p36.32-
p35.2, 1p21.3-p21.1, 1q32.1-q42.13, 2q14.1-q22.2, 4q33-q34.3,
6p25.1-p21.32 and 7p22.3-p13. Of the 156 identified genomic
clones, 104 mapped to these seven regions. The percentage of
genomic clones in the identified regions showing significant
differences varied between 25–100%, with the 1p21.3-p21.1
region showing the highest percentage of clones with significant
differences (see Table S2). The 1q32.1-q42.13 region showed
significantly lower copy number in MFHs compared to leiomyo-
sarcomas, whereas all the other six regions showed significantly
higher copy number.
Discussion
We have used array CGH to analyse DNA copy number
changes in a panel of 33 MFHs, in order to identify recurrent copy
number alterations at high-resolution and thus identify loci that
may contain novel candidate oncogenes and/or tumour suppres-
sor genes. The tumours were pathologically revised at the time of
the study and classified according to the latest WHO classification
[1]. The panel consisted mainly of the most common MFH
subtype, spindle cell/pleomorphic MFHs, as well as some
myxofibrosarcomas and pleomorphic MFHs with giant cells
(Table 1). Hierarchical clustering of the samples based on the
DNA copy number changes showed no associations between the
clustering pattern and the tumour subtype or the other clinical
features (Figure 1), and no chromosomal regions with significantly
different DNA copy number between the primary tumours and
recurrences were found.
The samples showed numerous gains and losses of large
chromosomal regions. Forty-one minimal recurrent regions were
identified as altered in at least 30% of the tumour samples, of
which 24 showed increased and 17 decreased copy number
(Table 2). The most common gains observed were in chromosome
1, where minimal recurrent regions in 1p33-p32.3, 1p31.3-p31.2
and 1p21.3 were gained in 58% of the samples, whereas 1q21.2-
q21.3 was gained in 55% of the samples. Increased copy number
of regions in chromosome 1 has been frequently observed in
MFHs previously, in particular 1p31 and 1q21-q22 [5,6,8,9].
High-level amplification of the 1q21-q22 region has been
Figure 3. Patient survival curves. Kaplan-Meier plots with overall survival curves for (A) patients with gain of 1p33-p32.3 (n=19) and patients
with normal copy number or loss (n=14) and (B) patients with gain of 1p21.3 (n=19) and patients with normal copy number or loss (n=14).
doi:10.1371/journal.pone.0015378.g003
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types of sarcomas, like osteosarcomas [17,18].
Although, gain of the 1p31 region has previously been associated
with a trend to decreased overall patient survival in MFHs [5], no
such association was seen in this tumour panel. On the contrary,
gain of 1p33-p32.3 and 1p21.3 were significantly associated with
better patient survival (P=0.021 and 0.046, respectively) (Figure 3A
and –B). However, these aberrations were not identified as
independent prognosticfactorsinthemultivariate analysisincluding
all experimental and clinical variables significantly associated with
survival. Notably, the other region in 1p frequently gained, 1p31.3-
p31.2, was not associated with better (or worse) patient survival.
Gain of 20q13.2 was also identified in 55% of the samples, and
increased copy number of regions in 20q has also been frequently
observed in MFHs previously [4,6,8,9]. Other regions of frequent gain
including 5p14.3, 4q12, 9q21.33-q31.3 and 19q13.11-q13.2 (Table 2)
Figure 4. Comparison between MFHs and leiomyosarcomas. (A) Hierarchical clustering dendogram of 33 MFHs and 44 leiomyosarcomas
using DNA copy number ratios relative to a pool of normal diploid DNA. Black, MFHs; grey, leiomyosarcomas. (B) Graphical representation of genomic
clones identified by SAM to be significantly different between the MFHs and leiomyosarcomas. The lines represent the chromosomal position of the
156 identified genomic clones. Green, higher copy number in MFHs compared to leiomyosarcomas; red, lower copy number.
doi:10.1371/journal.pone.0015378.g004
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However, this higher resolution analysis also identified rather frequent
regions of gain in MFHs (around 40%), not previously reported as
such, including 7q11.21-q11.22, 18q11.2, 3p21.1-p11.2 and 6q12-q13.
The most frequent losses observed were in chromosome 10 and
13, where minimal recurrent regions in 10q25.3-q26.11, 13q13.3-
q14.2 and 13q14.3-q21.1 were lost in 64% of the samples.
Decreased copy number of regions in chromosome 13 has been
frequently observed in MFHs previously [4,5,6,8,9,10,20]. The
losses may involve the whole chromosome arm, or more specific
regions like 13q14 and 13q21-q22. Loss of regions in chromosome
13 is a frequent finding in other types of sarcomas as well
[7,12,21,22], and the well-known tumour suppressor gene RB1 is
considered to be the prime candidate target for the deletion
involving the 13q14 region. The RB1 gene has also previously
been suggested to be the target for loss of the 13q14-q21 region in
MFHs [20].
Loss of regions of chromosome 10 is also a frequent finding in
MFHs [4,6,8], as well as other types of sarcomas [12,21,22]. The
minimal recurrent region identified here was 10q25.3-q26.11, and
frequent loss of 10q25 has also been previously reported in MFHs
[6]. Other recurrent regions of loss included 2q36.3-q37.2 (61% of
the samples), 1q41 (55%), 16q12.1-q12.2 (52%), 2p25.3-p25.1,
11q14.1, 11q14.3-q21 and 11q23.3-q25 (all 48%), all previously
reported as recurrent in MFHs [4,6,7,8]. However, recurrent
regions of loss not previously reported as frequent in MFHs were
also identified, including 8p23.2-p22 (48% of the samples) and
5q23.2-q31.3 (33%).
Although several of the minimal recurrent regions identified
were small in size, a number of genes are located in these
segments, making it challenging to identify the target genes for the
chromosomal aberrations based on these data only. Further
analysis utilizing gene expression and functional data would be
necessary for determining the most likely candidate target genes.
One of the main challenges in diagnosing MFHs is to
distinguish them from other malignant tumours with a similar
degree of cellular pleomorphism, like pleomorphic leiomyosarco-
mas, rhabdomyosarcomas and liposarcomas [3]. In order to
investigate differences in DNA copy number aberrations between
MFHs and leiomyosarcomas, a comparison with similar array
CGH data from a panel of 44 leiomyosarcomas ([12] and Kresse
et al., unpublished) was done. Hierarchical clustering of the
samples based on the DNA copy number changes showed no
major differences in the clustering pattern between the two tumour
types (Figure 4A), similar to what has been reported by others
[19,23].
Seven chromosomal segments represented by multiple signifi-
cant clones were identified as significantly different in copy
number between the MFHs and leiomyosarcomas; 1p36.32-p35.2,
1p21.3-p21.1, 1q32.1-q42.13, 2q14.1-q22.2, 4q33-q34.3, 6p25.1-
p21.32 and 7p22.3-p13 (Figure 4B). The 1q32.1-q42.13 region
showed significantly lower copy number in MFHs compared to
leiomyosarcomas, whereas all the other six regions showed
significantly higher copy number. In a previous study comparing
CGH data from 102 MFHs and 82 leiomyosarcomas, several
chromosomal regions with differences in copy number between
the two groups were identified [23]. Interestingly, the 1ptel-1p31
and 7p22-p15 regions were also shown to be more frequently
gained in the MFHs, whereas the 1q32-qtel region was shown to
be more frequently gained in the leiomyosarcomas, consistent with
our findings. In addition, loss of the 6p region was more frequent
in the leiomyosarcomas [23]. However, in another study
comparing array CGH data from 31 MFHs/UPSs and 18
leiomyosarcomas, no chromosomal regions with significant
differences in copy number were found using SAM, only a small
set of single clones [19]. It is still uncertain whether MFHs
represent a separate entity or if the majority correspond to highly
pleomorphic leiomyosarcomas, but our work identified genomic
differences between these two tumour groups and supports the
existence of two separate entities.
Previously it was shown that a subset of MFHs could correspond
to undifferentiated liposarcomas since these showed similar
chromosomal aberrations, like high-level amplification of the
12q14-q15 region [24]. Further it was demonstrated that these
MFH samples showed frequent co-amplification of either 1p32 or
6q23, which was not observed in the liposarcomas, suggesting that
the lack of differentiation may be a consequence of amplification
of target genes located in these regions, like the ASK1 (MAP3K5)
gene in 6q23 [24,25]. Increased copy number of regions in 12q
was observed in this tumour panel as well, but not as frequent.
Only two samples showed high-level amplification of parts of the
region, but co-amplification of 1p32 or 6q23 was not identified in
these samples (see Table S1), suggesting that this is not a general
feature.
In summary, our array CGH analysis of a panel of MFHs
identified a number of recurrent regions of gain and loss, some of
which were associated with clinical features. Several of the regions
have also been identified as frequently altered in previous CGH
studies of MFHs, and may be characteristic for this type of
tumours, although not necessarily specific. A comparison with a
panel of leiomyosarcomas showed that the two tumour types could
not be distinguished based on the overall DNA copy number
profiles, but several specific chromosomal regions with significant
differences in copy number were identified. If consistently found in
larger panels of tumours, these aberrations may be used as
additional tools for the differential diagnosis of MFHs and
leiomyosarcomas.
Supporting Information
Figure S1 Genome-wide ratio plots of 33 MFHs.  (PDF)
Figure S2 Kaplan-Meier plots with overall survival curves for A)
female patients (n=14) and male patients (n=19) and B) patients
with metastasis at diagnosis (n=4) and patients without (n=29). 
Table S1 Identification of minimal recurrent regions in malignant
fibrous histiocytomas using ACE (FDR=0.0001 and medium
sensitivity). Orange areas indicate increased DNA copy number
detected by ACE and green areas decreased DNA copy number;
Bold numbers indicate high-level amplification (log2.1) or homo-
zygous deletion (,21); Red triangles indicate missing values imputed
via a K-Nearest Neighbor algorithm normalization using SAM;
Recurrent regions are defined in light grey ($30%) and grey ($50%)
and minimal recurrent regions in black frames. (XLS)
Table S2 Identification of genomic clones significantly different
in copy number between MFHs and leiomyosarcomas using SAM.
Genomic areas significantly different are indicated in black frames. 
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